Salarius Pharmaceuticals, Inc. announced that it has regained compliance with Nasdaq’s Minimum Bid Price Requirement, meeting a key milestone in regaining compliance with all Nasdaq listing standards. The company has until October 20, 2025, to meet the Equity Standard Requirement. Additionally, Salarius is undergoing a one-year monitoring period and is in the process of merging with Decoy Therapeutics, Inc., a biopharmaceutical company specializing in peptide conjugate therapeutics for respiratory diseases and GI oncology. Decoy expects to advance its lead asset, a pan-coronavirus antiviral, to an IND filing with the FDA within the next 12 months.

Read more at GlobeNewswire: Salarius Pharmaceuticals Regains Compliance with Nasdaq